MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergic neurons"

  • MDS Virtual Congress 2020

    Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy

    V. DJ, S. Chandra (New Haven, CT, USA)

    Objective: To evaluate the role of auxilin in the pathogenesis of Parkinson’s disease (PD). Background: Auxilin or DNAJC6, a brain-specific co-chaperone plays central role in…
  • MDS Virtual Congress 2020

    Effects of exosomes devised from dopaminergic neurons overexpressing α-synuclein on autophagy and inflammation in microglia

    Y. Liang, L. Bu, E. Tao (Guangzhou,Guangdong, China)

    Objective: The aim of this study was to investigate whether the exosomes secreted by dopaminergic neurons over-expressing α-synuclein could regulate the inflammation of microglia via…
  • MDS Virtual Congress 2020

    L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production

    S. Martin, V. Jones, J. Taylor, S. Lane, J. Ehlting, A. Helton, P. Walter (Victoria, BC, Canada)

    Objective: Naturally-occuring quantities of in vivo neuromelanin (NM) are low, and the collection of NM from tissue involves laborious extraction and isolation. Thus, in vitro…
  • MDS Virtual Congress 2020

    The Influence of 3-Phenoxybenzoic Acid in Dopaminergic Degeneration

    F. Wan (Wuhan, China)

    Objective: 3-phenoxybenzoic acid (3-PBA) is a metabolite of Fenpropathrin (FEN). The emphasis of this paper is on the relationship between 3-PBA and Dopaminergic Degeneration. Background:…
  • 2019 International Congress

    Neuroprotective effect of Yerba mate (Ilex paraguariensis) in a Drosophila model of Parkinson ’s disease

    P. Ballestero, A. Bernardi, H. Hauche Pedernera, O. Gershanik, N. Muraro, J. Ferrario (Capital Federal, Argentina)

    Objective: To test the neuroprotective capacity of Yerba Mate (YM) in an in vivo model of Parkinson's disease. Background: Parkinson's disease (PD) is caused by the…
  • 2019 International Congress

    Assessment of neuronal morphology to determine the differential susceptibility to Parkinson’s disease using MPTP in two genetically distinct mice strains

    B. Bhaduri, I. Datta, R. Yadav, P. Alladi (Bangalore, India)

    Objective: To delineate the contribution of neuronal-dendritic structure in the substantia nigra and striatum, in conferring differential susceptibility to Parkinson’s disease, using two genetically distinct…
  • 2019 International Congress

    Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics and α-synuclein stability

    a. Mori, T. Hatano, T. Inoshita, K. Shiba-Fukushima, T. Koinuma, C. Yamashita, A. Okuzumi, Y. Imai, n. Hattori (Tokyo, Japan)

    Objective: To investigate the mechanism of α-synuclein (α-Syn) aggregation. Background: PLA2G6 has been isolated as the gene responsible for an autosomal recessive form of Parkinson’s…
  • 2019 International Congress

    Apigenin loaded Phospholipid based nanoemulsion in Therapeutics of Parkinson’s Disease Via Attenuation of Oxidative Stress and Upregulation of Dopamine.

    M-R. Rahman, V-K. Kumar (Allahabad, India)

    Objective: The aim of the present study was to develop, optimizes and evaluate the antiparkinson effects of apigenin loaded phospholipid based nanoemulsion via attenuation of…
  • 2019 International Congress

    DNAJC13 in Parkinson’s disease; characterization of the p.N855S knock-in mouse model

    J. Follett, J. Fox, E. Gustavsson, M. Farrrer (Vancouver, BC, Canada)

    Objective: To study the effects of DNAJC13 p.Asn855Ser mutant gene dysfunction in a physiological context, and to help define molecular mechanisms for disease, using a…
  • 2019 International Congress

    Therapeutic intervention of LRRK2 kinase inhibitors in Vps35 p.D620N Parkinsonism

    I. Tatarnikov, J. Follett, J. Fox, M. Farrer (Vancouver, BC, Canada)

    Objective: To explore the therapeutic potential of LRRK2 kinase inhibitors in a Vps35 p.D620N mouse model of Parkinsonsim. Background: The discovery of a missense mutation, Vps35 p.D620N…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley